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Abstract 
 
Objectives: To monitor epidemiological trends of infectious meningitis (bacterial and viral) 
and encephalitis in Denmark. 
Methods: Nation-wide prospective observational study of all cases with proven community-
acquired infectious meningitis and encephalitis in adults treated in all departments of 
infectious diseases in Denmark from 1st of January 2015 to 30th of June 2016. We included 
data on symptoms, aetiology, treatment and outcome assessed by the Glasgow Outcome Scale 
(GOS) 30-days after discharge. GOS 1-4 was categorised as unfavourable outcome.  
Results: During 18 months of observation, we identified 252 cases of viral meningitis 
(3.6/100,000/year), 214 cases of bacterial meningitis (3.1/100,000/year), and 96 cases of 
infectious encephalitis (1.4/100,000/year). In bacterial meningitis, Streptococcus pneumoniae 
was most frequent (n=101) followed by Staphylococcus aureus (n=24) and β-haemolytic 
streptococci (n=14). Meningococcal meningitis was rare (n=11). In encephalitis, Herpes 
simplex virus-1 was most common (n=37) followed by Varicella zoster virus (n=20), while 
Varicella zoster virus (n=61) was most common in viral meningitis followed by enterovirus 
(n=50) and Herpes simplex virus-2 (n=46). Case fatality and unfavourable outcome occurred 
in 31/214 (15%) and 96/214 (45%) with bacterial meningitis and in 5/96 (5%) and 55/89 
(62%) with encephalitis. For viral meningitis, unfavourable outcome occurred in 41/252 
(17%). 
Conclusions:  The epidemiology and clinical presentation of the examined central nervous 
system (CNS) infections differed considerably and bacterial meningitis was more frequent 
than previously estimated. Overall prognosis remains poor for bacterial meningitis and 
encephalitis. Prospective nationwide clinical databases of CNS infections may be superior to 
epidemiological monitoring based on notifications or laboratory systems. 
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Introduction:  
Central nervous system (CNS) infections range from mild-moderate viral meningitis to life-
threatening diseases like acute bacterial meningitis or Herpes simplex virus encephalitis. Due 
to the relative rarity of the diseases, most contemporary studies rely on retrospective 
retrieval of information with inherent limitations. The majority of studies have examined 
selected CNS infections and some were hampered by incomplete inclusion and notification 
systems [1-9]. Although viral meningitis is generally considered a benign disease, some 
studies suggest that subsequent cognitive impairment may be more prevalent than first 
assumed [10,11]. Bacterial meningitis and encephalitis remain severe diseases with case-
fatality rates of 10-30% and unfavourable outcomes in 40-60% [1,3,4,12]. 
Therefore, an overview of the burden of CNS infections is important and given the rarity of 
CNS infections, well-established multi-centre networks are required to carry out future 
clinical studies. In order to address these questions and to monitor epidemiological trends, we 
aimed to establish a high-quality prospective observational database of all CNS infections 
treated at departments of infectious diseases in Denmark. In the current study, we set out to 
examine the epidemiology, clinical characteristics and outcome of infectious meningitis and 
encephalitis.  
 
Methods:  
Setting 
The Danish Study Group of Infections of the Brain (DASGIB) was established in January 2014 
as a nationwide collaboration between infectious disease specialists with the aim to monitor 
epidemiological trends and conduct studies of CNS infections in Denmark. The parties agreed 
to prospectively register all CNS infections diagnosed and/or treated at all seven departments 
of infectious diseases in Denmark using a web-based case-report form (CRF). To ensure 
completeness of reported CNS infections annual searches of selected ICD-10 codes 
(Supplementary Table 1) are performed in local administrative databases at each department. 
According to the Danish Board of Health, all patients with CNS infections are to be treated at 
departments of infectious diseases. In general, diagnostic work-up and treatment were left at 
the discretion of the local physician and therefore not standardised. For bacterial meningitis, 
national guidelines are available (www.infmed.dk/udgivelser - in Danish). Serum 
procalcitonin levels are not routinely used for CNS infections in Denmark. 
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In Denmark, all inhabitants are assigned a unique personal identifier at birth or immigration 
by which all health-care information can be obtained at an individual-based level. Treatment 
in primary, secondary and tertiary care is tax-financed and free of charge at the point of 
delivery. The population above 15 years of age in Denmark was 4,628,949 in January 2015 
and 5,659,715 for the entire population [13].  
 
Study population 
All patients above 15 years of age were prospectively included in the DASGIB cohort by the 
principal investigator at each site if they had a clinical presentation suggestive of CNS 
infection (e.g. any combination of neck stiffness, fever, headache or altered mental status) and 
either (i) Positive CSF culture or positive bacterial/viral DNA-based analysis for (community-
acquired) pathogens in the CSF or (ii) a positive blood culture and CSF leukocytes >10/mL or 
(iii) CSF leukocytes > 10/mL without any alternative diagnoses more likely to explain the 
patients’ conditions. Exact definitions of the included CNS infections as well as vaccinations 
policies for CNS pathogens are provided in the supplementary material. Quality control of 
case enrolment was ensured by ad hoc case-to-case discussions and at study group meetings 
2-3 times a year. During data management for this study, local investigators were queried if 
case report forms contained outliers or unusual values. We excluded patients with hospital-
acquired CNS infections as defined by the Centers for Disease Control and Prevention [13] or 
an implanted neurosurgical device. This study examined patients included during 18 months 
from 1st of January 2015 until 30th of June 2016. 
  
Patient data 
We prospectively recorded baseline information on demographics, time and place of 
admission, exposures, as well as clinical signs and symptoms at day of admission. Confusion 
was defined as disorientation in person, time or place at admission. Patients were categorised 
with an altered mental status at admission if the Glasgow Coma Scale (GCS) was below 14. 
During the course of hospitalization we noted antimicrobial treatment, cranial imaging and 
laboratory results from the departments of biochemistry, radiology and microbiology. Time of 
admission was obtained in prioritised order from the ambulance charts or notifications of 
arrival by secretaries or nurses in the emergency departments. Timing of lumbar puncture 
and cranial imaging was extracted from the electronic records at the departments of 
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biochemistry or radiology while timing of antibiotic therapy for meningitis was identified in 
electronic medication systems. Time to lumbar puncture, cranial imaging and antibiotic 
therapy was calculated as time from arrival at hospital to each of the above events.  
At 30 days after discharge outcome was assessed according to the Glasgow Outcome Scale 
(GOS): 1. Death, 2. A vegetative state, 3. Severe sequelae and dependency upon others in daily 
life, 4. Moderate sequelae but with the ability to live independently, and 5. No or only mild 
sequelae [14]. GOS scores of 1-4 were considered unfavourable outcome. 
 
Statistical analyses 
Contingency tables were constructed to describe baseline demographics. Proportions are 
presented as n/N with 95% confidence intervals (95% CIs) and continuous variables as 
medians with interquartile ranges (IQR). We used Stata MP® version 14.2 for statistical 
analyses. 
 
Ethical considerations 
The Danish Data Protection Agency approved the DASGIB cohort (record no. 2012-58-0018) 
and establishment of a biobank of CSF and blood samples from these patients (record no. 
2013-41-2502). Approval from the Danish Board of Health or an ethical committee was not 
required for this study. The study is reported according to STROBE guidelines. 
 
Results: 
During 1.5 years of study, we observed 252 cases of viral meningitis (3.6/100,000/year), 214 
cases of bacterial meningitis (3.1/100,000/year) and 96 cases of encephalitis 
(1.4/100,000/year). A few survivors at discharge were tourists (n=2) and thus unavailable for 
30-day follow-up.  
 
Patients with bacterial meningitis presented with neck stiffness in 111/197 (56%), altered 
mental status in 152/201 (76%) and fever ≥38.0°C in 140/204 (69%) of patients (Table 1). 
The meningitis triad (neck stiffness, altered mental status and fever) was present in 59/214 
(28%) of patients. We observed a median CSF leukocytes of 937 x 106/mL (IQR 231-4137), a 
median CSF protein of 2.3 g/L (IQR 1.0-5.1) and a median CSF:blood glucose index of 0.26 
(IQR 0.04-0.48). The aetiology was predominated by Streptococcus pneumoniae 
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(1.5/100,000/year), Staphylococcus aureus (0.3/100,000/year) and β-haemolytic streptococci 
(0.2/100,000/year) (Table 2). Twelve patients presented with symptoms of CNS infection at 
admission and had concomitant endocarditis of which eight were caused by S. aureus, two by 
β-haemolytic streptococci, and one by α-haemolytic streptococcus and Haemophilus 
influenzae each. Another eight patients with bacterial meningitis had concomitant 
spondylodiscitis of which three were caused by S. aureus, two by β-haemolytic streptococci, 
two by S. pneumoniae and one by Escherichia coli. In total, 11/24 of cases of S. aureus 
meningitis were associated with either endocarditis or spondylodiscitis. 
The median time from admission to lumbar puncture and antibiotic therapy for meningitis 
was 3.7 hours (IQR 1.8-8.8) and 3.3 (IQR 1.5-10.0), respectively. Cranial imaging was 
performed before lumbar puncture in 99/214 (46%) of patients and 160/212 (75%) were 
given empiric adjunctive dexamethasone treatment. In comparison of cases treated with vs. 
without dexamethasone, case-fatalities were 21/160 (13%) vs. 9/52 (17%), p=0.45 and 
unfavourable outcomes 30-days after discharge were 70/160 (44%) vs. 24/52 (48%), p= 0.7. 
Specifically for pneumococcal meningitis treated with or without dexamethasone, case 
fatalities were 8/85 (9%) vs. 3/15 (20%), p=0.23 and unfavourable outcomes 30-days after 
discharge were 34/85 (40%) vs. 9/15 (60%), p=0.15. 
 
Patients with encephalitis presented with headache in 56/76 (74%), fever ≥38.0°C in 44/91 
(48%), altered mental status in 27/71 (38%), seizures in 13/87 (15%) and focal neurological 
deficits in 13/90 (14%) patients (Table 3). Herpes simplex virus 1 (HSV-1) was the most 
common pathogen (0.5/100,000/year) followed by Varicella zoster virus (VZV) 
(0.3/100,000/year) (Table 2). The median time from admission to lumbar puncture, cranial 
CT and MRI were 13.1 hours (4.2-43.0), 4.2 hours (1.8-24.9) and 64.3 hours (31.5-112.6), 
respectively. Empiric acyclovir was administered in 90/93 (97%) patients before a formal 
diagnosis of encephalitis was established. At 30-days after discharge patients with 
encephalitis had a case fatality of 5/89 (5%) and the proportion with unfavourable outcome 
was 55/89 (62%).  
 
Patients with viral meningitis had a median age of 36 years (IQR 26-52) and presented with 
headache in 214/237 (90%), neck stiffness in 107/241 (44%), and fever ≥38.0°C in 92/236 
(39%) of patients (Table 4). The most common aetiology was VZV (0.9/100,000/year) 
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followed by enterovirus and Herpes simplex virus 2 (0.7/100,000/year for both) (Table 2).  
Unfavourable outcome 30-days after discharge occurred in 41/245 (17%) patients, of whom 
37 (15%) had a GOS of 4 and three had a GOS of 3 (advanced AIDS in two patients). One 
patient with viral meningitis of unknown aetiology died of a cerebral haemorrhage during 
hospitalization 
 
Discussion: 
We conducted a nationwide prospective observational cohort study of infectious meningitis 
and encephalitis in all adults diagnosed or treated at the seven departments of infectious 
diseases in Denmark. Except for a higher incidence of bacterial meningitis and a relatively 
large proportion caused by S. aureus and β-haemolytic streptococcal, the clinical 
presentations and outcomes were comparable to previous cohorts of each disease from 
similar settings. Among patients with viral meningitis, 37/252 (15%) had a GOS of 4 at 30-
days after discharge suggesting that return to previous lifestyle may take longer than often 
assumed. 
 
Laboratory-proven or clinically suspected cases of bacterial meningitis and invasive 
meningococcal disease (i.e. meningitis or sepsis) are notifiable by law in Denmark. Annual 
reports of incident cases based upon such notifications by clinicians are published by the 
Statens Serum Institute. We found a higher incidence of bacterial meningitis of 
3.1/100,000/year in adults (2.5/100,000/year using the entire population as denominator) 
than estimates of 2.4/100,000/year in both children and adults (entire population as 
denominator) from Statens Serum Institutute [15]. Such surveillance estimates have 
previously been shown to be inaccurate with an overall notification rate of 66% in Denmark 
[16]. Unusual pathogens such as S. aureus, E. coli and streptococci other than pneumococcus 
were particularly underreported, whereas the notifications of meningococcal and 
pneumococcal meningitis were almost complete. The observed difference in reported 
incidences of bacterial meningitis in our study may also be due to more vigilant inclusion of 
cases with unusual pathogens and cases with positive blood culture and CSF pleocytosis. Of 
note, use of DNA-based technologies for diagnosis of bacterial meningitis has not changed 
during the study period in Denmark.  
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Among cases of bacterial meningitis, we found that S. aureus and β-haemolytic streptococci 
were the second and third most frequent aetiologies. Although patients presented primarily 
with signs of CNS infection, a total of 20 cases had either concomitant endocarditis or 
spondylodiscitis. This is in contrast to a recent prospective study of CSF-culture positive cases 
in adults from the Netherlands in years 2006-14, where the overall incidence of bacterial 
meningitis was 0.94/100,000/year and N. meningitidis and L. monocytogenes were the second 
and third most frequent pathogens [1]. Two other registry-based studies of bacterial 
meningitis from the USA (children and adults) and Sweden (adults) also showed that 
meningococcal meningitis was the second most common cause in their settings [17,18]. The 
observed rarity of meningococcal meningitis in our cohort is supported by an overall low 
incidence of invasive meningococcal disease in Denmark notified to Statens Serum Institute 
[19]. Meningococcal disease is most frequent among children and adolescents and incidences 
may differ according to e.g. secular variations in study periods, demographic compositions of 
cohorts and vaccination programmes. Since the median age of the Dutch and Swedish groups 
was 61 years vs. 65 years in our cohort of adults and meningococcal vaccinations are not part 
of the childhood vaccination programme in Denmark, we consider secular variations as the 
most probable reason for the low incidence in our cohort.  
Compared to the Dutch cohort our bacterial meningitis patients less often had neck stiffness 
(56% vs. 74%), a higher GCS score (13 vs. 11), lower levels of CSF-leukocytes (937 x 106/mL 
vs. 2310 x 106/mL) and CSF-protein (2.3 g/L vs. 3.9 g/L) and higher levels of CSF:blood 
glucose ratio (0.26 vs. 0.04). This may reflect differences in bacterial aetiologies and inclusion 
criteria as only CSF-culture positive cases are included in the Dutch cohort, which could 
possibly be associated with more pronounced CNS inflammation. However, additional studies 
are needed to examine this finding further. In pneumococcal meningitis, adjunctive 
dexamethasone was associated with both lower case fatality and fewer unfavourable 
outcomes although statistical significance was not reached. This is most likely due to sample 
size limitations and dexamethasone should remain standard therapy for bacterial meningitis 
[20] 
Similar to other studies of encephalitis, we found that HSV-1 (39%) and VZV (21%) were the 
most frequent pathogens [3,4,21]. Interestingly, mortality at 30-days after discharge was only 
5% in our study which is comparable to a registry-based study from the USA in years 2000-
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10, but lower than the mortalities from prospective observational cohorts from the UK in 
years 2005-6 (12%) and France in year 2007 (10%). 
 
There are several limitations in our study. Selection bias may be present as patients had to 
have a lumbar puncture at some point during admission to be included and some cases e.g. 
viral meningitis may be diagnosed and treated at other departments than infectious diseases. 
This suggests that incidences could be higher than our estimates. However, according to the 
Danish Board of Health, the departments of infectious diseases are responsible for care of all 
patients with CNS infections, even when admitted to the intensive care unit, whereby such 
inaccuracies in incidences should be limited. Some patients were transferred from other 
hospitals to the department of infectious diseases and availability of all clinical information at 
admission may have been restricted in spite of the prospective design of our cohort. Although 
all patients with CNS infections are scheduled to at least a 30-day follow-up after discharge 
not all patients showed up for these visits. Still, given the unique civil registration number and 
setup of the Danish health care system, information on mortality and re-admissions are 
available, which strengthens estimates of mortality and curtails any missed serious new 
sequelae after discharge. Lastly, patient management including diagnostic measures and 
treatment was not standardised which may result in local differences in proportions with 
proven aetiologies and outcome of disease. 
 
In conclusion, the epidemiology and clinical presentation differed considerably among the 
examined CNS infections. Bacterial meningitis was more frequent than in previous studies 
with a considerable proportion caused by S. aureus and beta-haemolytic streptococci of which 
many had concomitant distant foci. Secular variation is a likely cause of few cases of 
meningococcal disease. Outcome remains poor for bacterial meningitis and encephalitis . 
Prospective nationwide clinical databases of CNS infections may be superior to 
epidemiological monitoring based on notifications or laboratory systems. 
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Table 1: 
Clinical characteristics at admission and outcome of 214 patients with bacterial meningitis. 
Categorical variables are presented as n (%) and continuous variables as medians with 
interquartile rates (IQRs).  
Characteristic  Observed patients (N) n (%), median (IQR) 
Age (years) 214 65 (54-73) 
Sex (females) 214 102 (48) 
Comorbidity* 210 67 (32) 
Duration of symptoms (days) 214 1 (0.4-3) 
Headache 158 123 (78) 
Neck stiffness 197 111 (56) 
Nausea/vomiting 187 62 (33) 
Seizures 190 19 (10) 
Petechiae/rash 197 23 (12) 
Fever (≥38.0°C) 204 140 (69) 
GCS 167 13 (10-15) 
Confusion 201 152 (76) 
Altered mental status (GCS<14) 167 97 (58) 
Focal neurological deficit 208 24 (12) 
Systolic blood pressure (mm Hg) 200 143 (121-165) 
CRP (mg/L) 209 188 (80-284) 
B-leukocytes (109/mL) 209 13.9 (9.8-19.3) 
B-thrombocytes (109/mL) 200 205 (142-263) 
CSF   
   Leukocytes (106/mL) 210 937 (231-4137) 
     - Polymorphonuclear (106/mL) 196 709 (158-3685) 
   Protein (g/L) 199 2.3 (1.0-5.1) 
   Glucose index 179 0.26 (0.04-0.48) 
   Lactate (mmol/L) 63 11.2 (5.1-15.0) 
Cranial imaging during admission 214 154 (72) 
   Infarction 154 33 (21) 
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   Opacification of ear, sinus or        
mastoid 
154 23 (15) 
   Otitis media/mastoiditis 154 15 (10) 
   Sinusitis 154 11 (7) 
   Intracranial haemorrhage 154 6 (4) 
   Generalised oedema 154 6 (4) 
   Hydrocephalus 154 5 (3) 
   Other findings** 154 11 (7) 
Cranial imaging before lumbar 
puncture  
214 99 (46) 
Time to lumbar puncture (hours) 201 3.7 (1.8-8.8) 
Time to antibiotics (hours) 200 3.3 (1.5-10.0) 
Adjunctive dexamethasone 212 160 (75) 
Intensive care unit admission 
(ICU) 
214 96 (45) 
Outcome   
   Case fatality rate 214 31 (15) 
      In patients admitted to ICU 96 20 (21) 
   Unfavourable outcome 30-days 
after discharge 
214 96 (45) 
GCS: Glasgow coma scale, CRP: C-reactive protein, CSF: Cerebrospinal fluid. 
*Comorbidity: Alcohol abuse, diabetes mellitus, solid or haematological cancer (including 
malignant melanoma, excluding other skin cancers), congenital or acquired immunodeficiency 
including HIV. **Includes six cases with ventriculitis, four with benign tumours, three with 
secondary brain abscess, three with secondary subdural empyema, two with hygroma, one 
with cerebritis, and one with malignant tumour and dural leakage each. 
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Table 2: Causative pathogens of infectious meningitis and encephalitis in adults treated in 
departments of infectious diseases in Denmark. Data is presented as n (%). 
Central nervous system 
infection 
Observed patients (N) Causative pathogen 
Bacterial meningitis   
   Proven aetiology 214 183 (86) 
      S. pneumoniae - 101 (47) 
      S. aureus - 24 (11) 
      β-haemolytic streptococci - 14 (7) 
      N. meningitidis - 11 (5) 
      α-haemolytic streptococci - 8 (4) 
      E. coli - 8 (4) 
      L. monocytogenes - 7 (3) 
      Other* - 10 (5) 
Encephalitis   
   Proven aetiology  96 64 (67) 
      HSV-1 - 37 (39) 
      VZV - 20 (21) 
      HSV-2 - 3 (3) 
      HIV - 2 (2) 
      TBE - 1 (1) 
      EBV - 1 (1) 
Viral meningitis   
   Proven aetiology 252 163 (65) 
      VZV - 61 (24) 
      Enterovirus - 50 (20) 
      HSV 2 - 46 (18) 
      EBV - 2 (1) 
      Chikungunya (traveller) - 1 (1) 
      HIV - 1 (1) 
      Influenza - 1 (1) 
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      TBE - 1 (1) 
HSV 1= Herpes simplex virus 1, VZV=Varicella zoster virus, HSV 2=Herpes simplex virus 2, 
HIV=Human immuno-deficiency virus, TBE=Tick-borne encephalitis virus, EBV=Epstein-barr 
virus. 
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Table 3: 
Clinical characteristics at admission and outcome of 96 patients with infectious encephalitis. 
Categorical variables are presented as n (%) and continuous variables as medians with 
interquartile rates (IQRs).  
Characteristic  Observed patients (N) n (%), median (IQR) 
Age (years) 96 65 (43-76) 
Sex (males) 96 42 (44) 
Comorbidity* 93 20 (22) 
Duration of symptoms (days) 96 3 (1-5.5) 
Headache 76 56 (74) 
Nausea/vomiting 87 30 (34) 
Fever (≥38.0°C) 91 44 (48) 
Confusion 94 69 (73) 
Altered mental status (GCS<14) 71 27 (38) 
Focal neurological deficit 90 13 (14) 
Seizures  87 13 (15) 
GCS 71 14 (12-15) 
Systolic blood pressure (mm Hg) 91 140 (126-156) 
CRP (mg/L) 92 5 (2-13) 
B-leukocytes (109/mL) 95 9.5 (7.7-11.5) 
CSF   
   Leukocytes (106/mL) 96 87 (39-178) 
      - Polymorphonuclear (106/mL) 81 2 (0-8) 
   Protein (g/L) 93 0.7 (0.5-1.1) 
   Glucose index 66 0.57 (0.47-0.64) 
   Lactate (mmol/L) 29 2.7 (2.1-3.0) 
MRI suggestive of encephalitis 80 46 (58) 
Time to lumbar puncture (hours) 90 13.1 (4.2-43.0) 
Time to cranial CT (hours) 72 4.2 (1.8-24.9) 
Time to cranial MRI (hours) 74 64.3 (31.5-112.6) 
Cranial imaging before lumbar 96 59 (61) 
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puncture  
Empiric acyclovir treatment** 93 90 (97) 
Empiric adjunctive 
dexamethasone**  
79 25 (32) 
Intensive care unit admission 95 24 (25) 
Outcome   
   Case fatality rate 96 5 (5) 
      In patients admitted to ICU 24 1 (4) 
   Unfavourable outcome 30-days 
after discharge 
89 55 (62) 
GCS: Glasgow coma scale, CRP: C-reactive protein, CSF: Cerebrospinal fluid. 
*Comorbidity: Alcohol abuse, diabetes mellitus, solid or haematological cancer (including 
malignant melanoma, excluding other skin cancers), congenital or acquired immunodeficiency 
including HIV. **Initiated before the aetiology was established. 
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Table 4: 
Clinical characteristics at admission and outcome of 252 patients with viral meningitis. 
Categorical variables are presented as n (%) and continuous variables as medians with 
interquartile rates (IQRs).  
Characteristic  Observed patients (N) n (%), median (IQR) 
Age (years) 252 36 (26-52) 
Sex (males) 252 119 (47) 
Comorbidity* 244 28 (11) 
Duration of symptoms (days) 252 2 (1-5) 
Headache 237 214 (90) 
Neck stiffness 241 107 (44) 
Nausea/vomiting 242 92 (38) 
Seizures  238 5 (2) 
Fever (≥38.0°C) 236 92 (39) 
Confusion 243 43 (17) 
GCS 212 15 (15-15) 
Systolic blood pressure (mm Hg) 229 130 (120-141) 
CRP (mg/L) 242 4 (2-15) 
B-leukocytes (109/mL) 244 8.5 (6.7-10.7) 
CSF   
   Leukocytes (106/mL) 252 125 (37-270) 
     - Polymorphonuclear (106/mL) 225 6 (1-30) 
   Protein (g/L) 246 0.7 (0.5-1.0) 
   Glucose index 192 0.55 (0.49-0.62) 
   Lactate (mmol/L)** 88 2.2 (1.8-2.8) 
Cranial imaging before lumbar 
puncture  
252 84 (33) 
Empiric acyclovir treatment 240 203 (85) 
Empiric adjunctive 
dexamethasone 
206 86 (42) 
Time to lumbar puncture (hours) 237 3.8 (1.5-8.4) 
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Outcome   
   Case fatality rate 252 1 
   Unfavourable outcome 30-days 
after discharge 
245 41 (17) 
GCS: Glasgow coma scale, CRP: C-reactive protein, CSF: Cerebrospinal fluid. 
*Comorbidity: Alcohol abuse, diabetes mellitus, solid or haematological cancer (including 
malignant melanoma, excluding other skin cancers), congenital or acquired immunodeficiency 
including HIV. **Only a few centres perform CSF-lactate analyses. 
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Supplementary material: 
 
The Danish Study Group of Infections of the Brain (DASGIB) consists of: 
 
Jacob Bodilsen, Department of Infectious Diseases, Aalborg University Hospital, Aalborg, 
Denmark (Secretary) 
 
Merete Storgaard, Department of Infectious Diseases, Aarhus University Hospital Skejby, 
Aarhus, Denmark 
 
Lykke Larsen, Department of Infectious Diseases, Odense University Hospital, Odense, 
Denmark 
 
Jannik Helweg-Larsen, Department of Infectious Diseases, Rigshospitalet, Copenhagen, 
Denmark 
 
Lothar Wiese, Department of Pulmonary and Infectious Diseases, Sjællands University 
Hospital Roskilde, Roskilde, Denmark 
 
Birgitte Rønde Hansen, Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, 
Denmark 
 
Christian Brandt, Department of Pulmonary and Infectious Diseases, Nordsjællands Hospital 
Hillerød, Hillerød, Denmark 
 
Christian Østergaard, Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen, 
Denmark 
 
Henrik Nielsen, Department of Infectious Diseases, Aalborg University Hospital, Aalborg, 
Denmark (Chair) 
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Supplementary Table 1: 
Codes used for assessment of completeness of reported CNS infections. International 
Classification of Diseases (ICD), 10th version.  
A17 
A32.1 
A32.7 
A39.0 
A52.1-52.3 
A69.2 
A83 
A84 
A85 
A87 
A89 
B00.3-00.4 
B01.0-01.1 
B02.0-02.9 
B582 
B451 
B375 
G00 
G01 
G02 
G03 
G04 
G05 
G06 
G07 
 
Definitions of central nervous system infections used in the Danish Study Group of 
Infections of the Brain. 
For all cases with unproven pathogens, no alternative diagnosis than CNS infection was 
thought more likely after completed multidisciplinary diagnostic work-up. 
 
Viral meningitis: A clinical presentation with non-bacterial meningitis (e.g. headache, neck 
stiffness, photo- or phonophobia, fever) and cerebrospinal fluid leukocytes>10 cells/mL. We 
included both proven and suspected viral infections. For patients with undetermined 
pathogen CSF leukocytes> 10/mL was mandatory and the principal investigator used all 
available information to conclude whether the infection was most likely bacterial or viral. In 
case of doubt, patients were discussed with the DASGIB secretary and chair or at meetings.  
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Bacterial meningitis: A clinical presentation consistent with bacterial meningitis (e.g. 
headache, neck stiffness, fever, altered mental status) and proven bacterial aetiology (CSF or 
blood culture/DNA based technology or antigen tests). For patients in whom the bacteria 
could not be cultured or identified by DNA-based technologies, CSF leukocytes> 10/mL was 
mandatory and the principal investigator used all available information to conclude whether 
the infection was most likely bacterial or viral. In case of doubt, patients were discussed with 
the DASGIB secretary and chair or at meetings. Patients with mycobacterial meningitis were 
omitted for this study. 
 
Infectious encephalitis: A clinical presentation consistent with encephalitis (e.g. headache, 
fever, focal neurological deficit, altered mental status >24 hours) as defined the International 
Encephalitis Consortium (Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A, 
et al. Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus 
Statement of the International Encephalitis Consortium. Clin Infect Dis 2013;57:1114–28. 
doi:10.1093/cid/cit458.). We excluded cases of proven or suspected autoimmune 
encephalitis. 
 
Danish vaccination programmes for pathogens known to cause CNS infections: 
- Childhood vaccination programme 
o Diptheria-tetanus-pertussis-polio-H. influenzae and 13-valent conjugated 
pneumococcal vaccines at 3, 5 and 12 months of age. A booster of diphtheria-
tetanus-pertussis-polio is given at 5 years of age. 
o Measles, mumps and rubella are administered at 15 months of age with a 
booster at 4 years of age. 
o Conjugated vaccination for H. influenzae was introduced in 1993. For S. 
pneumoniae, a 7-valent conjugated vaccine was introduced in 2007 and 
replaced by a 13-valent vaccine in 2010. For pneumococcal vaccinations in 
adults please see below. 
 
- Recommendations of vaccination of risk groups in Denmark (adults and children): 
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o Conjugated meningococcal vaccines (Quadrivalent A, C, Y, W-135 and lately also 
specific conjugated vaccine for serogroup B) have been given to house-hold 
relatives of confirmed invasive meningococcal disease, but has never been part 
of the Danish childhood vaccination programme. 
o Since 2014, 13-valent conjugated pneumococcal vaccine is strongly 
recommended to patients with asplenia, cochlear implants, before organ 
transplantation, dural defects, immunosuppressive conditions (e.g. HIV or 
lymphoma) or after documented invasive pneumococcal disease (e.g. 
pneumonia, meningitis, bacteraemia). Eight weeks later a second vaccination 
with the 23-valent polysaccharide pneumococcal vaccine is advised.  
In Denmark, pneumococcal vaccination can also considered in patients with 
chronic heart failure, chronic obstructive pulmonary disease, chronic liver- or 
kidney disease, diabetes mellitus, age> 64 years, astma, b-cell immuno-
deficiency, smokers, occupational hazards (e.g. welders). 
 
 
 
 
 
 
